{"data":{"type":"company_profile","id":47827,"entity_id":"wefunder:company:47827","attributes":{"canonical_url":"https://wefunder.com/quadrant.biosciences","generated_at":"2026-06-15T22:17:59Z","updated_at":"2026-06-15T05:00:18Z","entity_ids":{"company":"wefunder:company:47827","slug":"wefunder:company_slug:quadrant.biosciences"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-15T22:17:59Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-15T05:00:18Z","as_of":"2026-06-15T22:17:59Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-15T05:00:18Z","as_of":"2026-06-15T22:17:59Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-15T22:17:59Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-15T22:17:59Z","confidence":"medium"}}},"company":{"id":47827,"entity_id":"wefunder:company:47827","slug":"quadrant.biosciences","name":"Quadrant Biosciences","tagline":"We develop novel, saliva based tests for Autism, COVID-19 and Parkinson's. ","elevator_pitch":"We develop\u0026nbsp;epigenetic saliva biomarkers including the world's first saliva test for autism. We recently received FDA emergency use authorization for a COVID-19 saliva test, and are currently working on developing tests for Parkinson's disease, concussion, and Anorexia nervosa.","story":"Leaders in the Development of Epigenetic Diagnostic ToolsQuadrant Biosciences is a life science company working with universities across the US to develop and commercialize epigenetic diagnostic solutions for autism spectrum disorder, Parkinson’s disease, and mild traumatic brain injury (concussion). Working closely with medical researchers such as SUNY Upstate Medical University and Penn State College of Medicine, we have developed a novel, saliva-based diagnostic platform called Clarifi®.In December 2019 we launched Clarifi ASD®, the world's first saliva test for autism spectrum disorder. The test, intended for children 18 months through six years of age, provides a probability of an autism diagnosis based on epigenetic markers in the saliva.Then the COVID-19 pandemic happened.Not long after we began to introduce Clarifi ASD to pediatric health care providers, the world was besieged by the COVID-19 pandemic. Our ability to access healthcare providers and share the scientific and practical utility Clarifi ASD provides to parents and physicians was greatly restricted by social distancing mandates and virus concerns which, in turn, limited our sales team’s ability to affect sales and increased commercial demand for Clarifi ASD. As a result, our sales of the Clarifi ASD test have been below expectations.So, we adapted!In response to the COVID pandemic, we immediately reduced our operating costs and, given our existing experience with RNA analysis - and the fact that COVID-19 is an RNA virus - we made the decision to pivot and work with our university partners to develop diagnostic tools for COVID-19. As a result, today we are involved in three significant, complementary COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.Watch this brief overview video of our company projects:Three Levels of Testing: A Comprehensive Approach to Assessing COVID-191. Individual Testing - Clarifi COVID-19 Test KitThe development of an individual saliva test for COVID-19 was a natural extension of our earlier work with Clarifi ASD®, which used a similar saliva collection methodology. Working in partnership with SUNY Upstate Medical University, we developed the \"Clarifi COVID-19 Test Kit by SUNY Upstate Medical and Quadrant Biosciences,\" a non-invasive and easy to administer swab that collects saliva which is then analyzed to determine the presence or absence of the SARS-CoV-2 virus. On September 22nd, we received Emergency Use Authorization (EUA) for the Clarifi COVID-19 Test Kit!The Clarifi COVID-19 Test Kit contains the saliva collection swab and the reagents needed to run the analysis and is available for use by high-complexity clinical laboratories serving patients through physicians' offices, urgent care clinics, and hospitals.2. Community/Municipal Screening: Wastewater SurveillanceThis project, funded by New York State, involves our collaboration with SUNY ESF, Upstate Medical University, Syracuse University, and global civil engineering firm Arcadis, to collect and analyze wastewater from the county and municipal sewer systems for the presence of the COVID-19 virus. Our analysis of wastewater samples provides local health officials and policymakers with early indications and information regarding the presence and preponderance of COVID-19 infections in these communities./3cb63078d5“This can be a real game-changer in the detection and monitoring of COVID-19. Information from this testing will allow municipalities to estimate COVID-19 transmission in real time, provide instant feedback on social distancing and reopening phases, help predict hospitalizations and provide confidence for locations with zero transmission to resume normal activity.”Richard Uhlig, Founder and CEO of Quadrant BiosciencesBecause this allows for large regions to be effectively tested for the presence of the COVID-19 virus, it provides a cost-effective and efficient way to screen residents in towns, cities, states, and universities, even in the absence of individual testing.3. Group/College Testing: Pooled TestingFinally, in response to an overwhelming need to efficiently test university students prior to attending classes, we have partnered with the Upstate Medical University to conduct pooled testing services for over 450,000 students preparing to begin the fall semester at SUNY schools.Each of these pooled tests for COVID-19 involves a single test of saliva samples collected from a group of 12 students. A negative test result means that all 12 students are presumed to be coronavirus-free. A positive test for the pool would mean every student in that group would need to be individually tested. Performing single tests of groups of students greatly reduces the cost of supplies, staffing, and time required to perform and interpret tests./71e98f83da\"SUNY Upstate Medical University's work with Quadrant Biosciences, a Start-Up New York company, has led to important breakthroughs in the development of saliva-based diagnostic solutions for neurological conditions such as autism spectrum disorder, Parkinson's disease and concussion injuries. The ability to transfer this innovative approach to assist colleges and universities with the unprecedented and complex work of preparing for the return of students to campuses across the state is an important part of New York's response to the COVID pandemic.\"Dr Mantosh Dewan, Interim President, SUNY Upstate Medical UniversityDisclaimers: *On September 22, 2020, The Clarifi COVID-19 Test Kit obtained Emergency User Authorization (EUA) by the Food and Drug Administration (FDA) to be used for the diagnosis fo SARS-CoV-2. The Clarifi COVID-19 test Letter of Authorization, along with the authorization Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients and authorized labeling are available on the FDA website.The Clarifi COVID-19 Test Kit has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. Clarifi COVID-19 has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.Despite the fact that we have the expertise, capability, and customer demand for these COVID-19 tests, the supplies needed to perform quantitative PCR are becoming increasingly difficult to obtain. This, and supply chain disruptions generally throughout the industry, could impair our ability to successfully commercialize one or all of these tests.But, we are still very much an Epigenetics Diagnostic Company!The Clarifi ASD®\u0026nbsp;Test - A Game-Changer for Autism DiagnosticsWe continue to maintain a focus on our core mission to develop epigenetic diagnostic tools, such as Clarifi ASD®, the world's first saliva test for autism spectrum disorder.What is it?Clarifi ASD is a saliva test that indicates the probability that a child has autism spectrum disorder.Who is it for?Clarifi ASD is being used primarily by pediatricians and family physicians with patients (18 months through 6 years of age) with a positive autism screening test or a clinical suspicion to aid in a formal diagnosis.Why is it needed?With 1 in 54 children being diagnosed with autism in the US according to the CDC, it is one of the most commonly diagnosed developmental disabilities in the country. Unfortunately, the current diagnostic process involves long wait times, largely the result of a small number of trained clinicians to administer behavioral tests. This, in turn, leads to delays in children receiving critical intervention services. If autism is identified and treatment is initiated early, the trajectory of a child's life can be positively changed.How Clarifi ASD Can Make a DifferenceFor the first time, clinicians have an accurate biological tool to aid in the early diagnosis of autism. With this simple saliva test, Clarifi ASD can:~ Help start services earlier when treatment is most effective~ Provide specialists biological data to support their behavioral assessments~ Facilitate cost savings through improving the diagnostic process\"What we’ve been able to do over the last 7 years, working together with a very dedicated team, is develop a test that utilizes saliva and can accurately distinguish whether a child has autism spectrum disorder or does not. This relies on a new type of molecular analysis that wasn't even possible until recently.\"Frank Middleton, Ph.D. Associate Professor of Neuroscience and Physiology, Biochemistry and Molecular Biology, Pediatrics, and Psychiatry and Behavioral Sciences.When was it launched?Clarifi ASD was launched commercially in the US in 49 states (excluding New York), in December 2019.Watch a short video about Clarifi ASD here:Who we areQuadrant Biosciences Inc was started in 2015 by Founder and CEO Rich Uhlig, and we have since grown to over 40 employees. Our team has a shared passion in being a part of positive changes in healthcare. “As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”Richard Uhlig, Founder and CEO, Quadrant BiosciencesCapital Raised to DateAs of January 2020, we have raised over $30 million in previous financing rounds from private investors who have recognized the value in how we intend to change the landscape of diagnostics in the future.Research Grants Received To DateWe have received numerous grants to support our research efforts.*(*The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.)Quadrant Biosciences in the MediaOur company has been featured many times in national news and scientific media outlets regarding our research and technology accomplishments in the areas of autism, concussion, and Parkinson's disease.Clarifi ASD is just the Beginning! Future products in the works.One of the most exciting things that we’ve discovered is that our Clarifi epigenetic diagnostic platform has applications for many other health issues. Diagnostic solutions for early-stage Parkinson's disease, mTBI/concussion, anorexia, and schizophrenia are currently in development. Several peer-reviewed research papers have already been published on the application of this approach to these worldwide neurological health concerns.We have numerous peer-reviewed publications supporting our scienceTo date, there have been 18 peer-reviewed papers published supporting our development of epigenetic biomarkers for autism, mild traumatic brain jury, Parkinson's disease, anorexia nervosa, and Pantothenate kinase-associated neurodegeneration disease (PKAN). These have been published in a variety of scientific journals including JAMA Pediatrics, Frontiers in Genetics, Journal of Neurotrauma, Journal of Oral Microbiology, Journal of Experimental Neuroscience, and Autism Research.Research PartnershipsWe are honored to partner with a number of outstanding research universities and organizations to help further the understanding of epigenetics.International Research PartnershipsWe also actively partnered with several international research organizations:European Autism Interventions, A Multicentre Study for Developing New Medications (EU-AIMS) - first Europe-wide collaboration between organizations with the goal of identifying markers of autism that would help in earlier and more accurate diagnosis, prognosis, and the development with new therapiesComprehensive Care Center for Disability (CAID) - centers in Santiago, San Juan, Higuey and Santo Domingo, the Dominican Republic dedicated to the evaluation, diagnosis and rehabilitation of children from zero to ten years with Autism Spectrum Disorder.Our Clinical Advisory BoardOur clinical advisory board comprises some of the leading autism and epigenetic researchers and clinicians. It is our privilege to work alongside these luminaries in the field to help families and children with autism.Want to learn more?For more information about the company, download the investor deck and visit Quadrant Biosciences www.quadrantbiosciences.com; for more information about Clarifi ASD visit www.clarifiasd.com.","location":"Syracuse, NY","website":"https://www.quadrantbiosciences.com","total_amount_raised":1339935,"total_investors":1299,"is_funded":false,"is_active":false,"quality_score":5,"related_urls":["https://wefunder.com/quadrant.biosciences","https://www.quadrantbiosciences.com"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/47827/xxl_cropped_Invest_in_Quadrant_Biosciences.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/47827/large_cropped_qb_only.png","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/47827/standard_cropped_Invest_in_Quadrant_Biosciences.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/47827/standard_cropped_Invest_in_Quadrant_Biosciences.jpg"},"links":{"company_url":"https://www.quadrantbiosciences.com","twitter_url":"http://twitter.com/quadbioinc","facebook_url":"https://www.facebook.com/quadrantbiosciences","instagram_url":"https://www.instagram.com/quadrant_biosciences"},"highlights":[],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"Applied our expertise in RNA analysis to co-develop FDA authorized COVID-19 saliva test with SUNY."},{"index":2,"claim_id":"claim-fact-2","value":"Developed \u0026amp; commercialized world's first saliva based epigenetic test for autism spectrum disorder."},{"index":3,"claim_id":"claim-fact-3","value":"Sales from our new saliva COVID-19 tests have exceeded $6.5MM to date since September 2020."},{"index":4,"claim_id":"claim-fact-4","value":"We are working with NY State to test municipalities' wastewater for COVID-19."},{"index":5,"claim_id":"claim-fact-5","value":"Working with SUNY on pooled saliva surveillance of returning college students for COVID-19."},{"index":6,"claim_id":"claim-fact-6","value":"Development of Parkinson's disease, concussion, and Anorexia Nervosa, diagnostic tools in progress."},{"index":7,"claim_id":"claim-fact-7","value":"Our company is led by a former Chairman \u0026amp; CEO of Morgan Stanley Bank, Richard Uhlig."}],"team":[{"id":729891,"entity_id":"wefunder:company_role:729891","user_entity_id":"wefunder:user:286625","role":"founder","name":"Richard Uhlig","title":"CEO and Founder","bio":"More than 25 years of business experience focused on the design and development of innovative products across various industries. Former CEO of Morgan Stanley Bank and CIO at Merrill Lynch Bank. Graduate of Cornell University.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/729891/square_cropped_Screen_Shot_2020-02-05_at_4.39.43_PM.jpg?1584113852","profile_url":"https://wefunder.com/ruhlig","linkedin_url":"https://www.linkedin.com/in/richard-uhlig-4a3a0b100/","related_urls":["https://wefunder.com/ruhlig"]},{"id":786616,"entity_id":"wefunder:company_role:786616","user_entity_id":"wefunder:user:316195","role":"employee","name":"Benjamin Perry","title":"President","bio":"Over 10 years of experience in the software development industry, with deep experience in cloud computing architecture, blockchain technology, and agile product management. Graduate of Cornell University.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/786616/square_cropped_MotionIntelligence_052016__RachelPhilipson_7445.9.jpg?1581275081","profile_url":"https://wefunder.com/benjaminperry","linkedin_url":"https://www.linkedin.com/in/benjamin-a-perry/","related_urls":["https://wefunder.com/benjaminperry"]},{"id":829922,"entity_id":"wefunder:company_role:829922","user_entity_id":"wefunder:user:486135","role":"employee","name":"Richard Bongo","title":"Chief Financial Officer","bio":"Over 30 years of experience in structured finance, Managing Director at one of Europe’s largest banks, positions at multiple Wall Street firms such as Lehman Brothers, Credit Suisse, Merrill Lynch and Bank of America. Graduate of Kings College.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/829922/square_cropped_rich_b.jpg?1584113345","profile_url":"https://wefunder.com/richardbongo","linkedin_url":"https://www.linkedin.com/in/richard-bongo-a80a0a7/","related_urls":["https://wefunder.com/richardbongo"]},{"id":729946,"entity_id":"wefunder:company_role:729946","user_entity_id":"wefunder:user:285905","role":"employee","name":"James Croke","title":"General Counsel","bio":"Experienced counsel to underwriters and issuers in the US and global public offerings and private placements as well as a writer and lecturer on legal and regulatory issues. Graduate of University of Kentucky and University of Notre Dame Law School.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/729946/square_cropped_jim_croke.jpg?1602189699","profile_url":"https://wefunder.com/jamescroke","linkedin_url":"https://www.linkedin.com/in/jim-croke-993991ab/","related_urls":["https://wefunder.com/jamescroke"]},{"id":821988,"entity_id":"wefunder:company_role:821988","user_entity_id":"wefunder:user:438090","role":"employee","name":"Dave MacLean","title":"Chief Marketing Officer","bio":"More than 25 years of business, legal and research experience including film production, entrepreneurship, litigation and research for Cornell University. Graduate of Cornell University and Buffalo Law School.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/821988/square_cropped_square_cropped_david_m_copy.jpg?1602189699","profile_url":"https://wefunder.com/davemaclean","linkedin_url":"https://www.linkedin.com/in/david-maclean-5928b8b4/","related_urls":["https://wefunder.com/davemaclean"]},{"id":837959,"entity_id":"wefunder:company_role:837959","user_entity_id":"wefunder:user:285888","role":"employee","name":"Syed Ameen","title":"Executive Vice President Corporate Strategy","bio":"Over 25 years of experience as an investment banker, founder and portfolio manager of Tevere Capital. He led multiple trading desks at Bank of America, Lehman Bros, and Merrill Lynch. Graduate of the University of Pennsylvania.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/837959/square_cropped_Naved_web.jpg?1602189699","profile_url":"https://wefunder.com/syedameen","linkedin_url":"https://www.linkedin.com/in/naved-ameen-b04347136/","related_urls":["https://wefunder.com/syedameen"]},{"id":845611,"entity_id":"wefunder:company_role:845611","user_entity_id":"wefunder:user:542157","role":"employee","name":"Jeremy Williams","title":"Chief Technology Officer","bio":"Experienced developer and leader spanning complex systems integration, mapping software used by state and municipal governments to manage geo-spatial data, and applications for research data analysis and dissemination. Graduate of Cornell University","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/845611/square_cropped_jeremy_williams.jpg?1602189699","profile_url":"https://wefunder.com/jeremywilliams4","linkedin_url":"https://www.linkedin.com/in/jeremy-williams-datadev/","related_urls":["https://wefunder.com/jeremywilliams4"]},{"id":845623,"entity_id":"wefunder:company_role:845623","role":"employee","name":"Chris Horacek","title":"Deputy General Counsel","bio":"Over 30 years' experience working in healthcare arena, and related areas of regulatory compliance and patent protection.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/845623/square_cropped_chris-horacek-deputy-general-counsel-quadrant-biosciences.jpg?1602189723","linkedin_url":"https://www.linkedin.com/in/chrishoracek/","related_urls":[]},{"id":846705,"entity_id":"wefunder:company_role:846705","user_entity_id":"wefunder:user:541395","role":"employee","name":"Kayla Wagner","title":"Vice President of Product Management","bio":"Experienced researcher with a career dedicated to working with children and adolescents with neurodevelopmental disorders in both clinical and research settings. Graduate of Syracuse University.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/846705/square_cropped_kayla-wagner-vice-president-product-management-quadrant-biosciences-e1573855252152-200x200.jpg?1602189699","profile_url":"https://wefunder.com/kaylawagner","linkedin_url":"https://www.linkedin.com/in/kayla-wagner-a33210155/","related_urls":["https://wefunder.com/kaylawagner"]},{"id":837930,"entity_id":"wefunder:company_role:837930","role":"employee","name":"Bryan Greene","title":"Chief Operating Officer","bio":"More than 10 years of experience in medical device operations, manufacturing, validation, and new product introduction. Graduate of Clarkson University.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/837930/square_cropped_bryan_greene_copy.jpg?1602189699","linkedin_url":"https://www.linkedin.com/in/bryan-greene/","related_urls":[]}],"featured_investors":[],"investor_memos":[],"tab_counts":{"posts":60,"ask_questions":100,"featured_investors":0,"faq_entries":5},"active_fundraises":[{"id":37723,"entity_id":"wefunder:fundraise:37723","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"custom","security_type":"custom","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":50000.0,"funding_started_at":"2020-09-26T00:09:34Z","funding_closed_at":"2021-02-22T05:04:41Z","auto_close_at":"2021-02-19T04:59:59Z"},{"id":28398,"entity_id":"wefunder:fundraise:28398","state":"successful","offering_type":"RegA+","funding_type":"note","structure":"convertible_note","security_type":"debt","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":50000.0,"funding_started_at":"2020-03-09T17:44:46Z","funding_closed_at":"2020-08-16T05:01:54Z","auto_close_at":"2020-08-16T03:59:59Z"}],"latest_fundraise":{"id":37723,"entity_id":"wefunder:fundraise:37723","state":"successful","offering_type":"4(a)(6)","structure":"custom","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2020-09-26T00:09:34Z","funding_closed_at":"2021-02-22T05:04:41Z","terms":{"eb":null,"nb":null,"txt":null}},"recent_posts":[{"id":142054,"entity_id":"wefunder:feed_item:142054","type":"FeedItem::Update","visibility":"public","title":"One Day Left to Invest!","preview":"There's only one day left to invest with\u0026nbsp;Quadrant Biosciences!\u0026nbsp;Our offering closes tomorrow, February 18th. Click here to learn more.\u0026nbsp;","published_at":"2021-02-17T15:43:08Z","author_name":"Dave MacLean","url":"/feed/142054","canonical_url":"https://wefunder.com/feed/142054"},{"id":142014,"entity_id":"wefunder:feed_item:142014","type":"FeedItem::Update","visibility":"public","title":"Offering Closing Soon","preview":"Thursday\u0026nbsp;is the last day to invest with Quadrant Biosciences! Click here to learn about our offering.","published_at":"2021-02-16T15:34:09Z","author_name":"Dave MacLean","url":"/feed/142014","canonical_url":"https://wefunder.com/feed/142014"},{"id":141921,"entity_id":"wefunder:feed_item:141921","type":"FeedItem::Update","visibility":"public","title":"One Week Left to Invest","preview":"Click on the graphic above or here\u0026nbsp;to go to our Wefunder page.","published_at":"2021-02-11T23:23:51Z","author_name":"Dave MacLean","url":"/feed/141921","canonical_url":"https://wefunder.com/feed/141921"},{"id":141877,"entity_id":"wefunder:feed_item:141877","type":"FeedItem::Update","visibility":"public","title":"Quadrant Concussion Research in the News","preview":"Some non-COVID news for a change! Our on-going research efforts into developing a saliva test to aid the diagnosis of concussions has received some attention in the news recently.\u0026nbsp; Check out one of the recent news\u0026nbsp;stories here or click on the image below.\u0026nbsp;And don't forget the investment opportunity closes on February 18th.\u0026nbsp;\u0026nbsp;Click here to go to our Wefunder page.\u0026nbsp;","published_at":"2021-02-10T22:22:34Z","author_name":"Dave MacLean","url":"/feed/141877","canonical_url":"https://wefunder.com/feed/141877"},{"id":141736,"entity_id":"wefunder:feed_item:141736","type":"FeedItem::Update","visibility":"public","title":"Offering Closing Soon! A Note from CEO Rich Uhlig","preview":"Hi everyone, I hope you and your families are staying safe and healthy.\u0026nbsp;\u0026nbsp;I am writing to let you know that Quadrant Biosciences’ offering will close on February 18. My colleagues and I are grateful for your continuing support, both financial and moral, during the past year. I am proud of our team’s hard work and resilience as we successfully navigated some very challenging and unprecedented waters during this pandemic. Our prospects, particularly in relation to increased sales of ou...","published_at":"2021-02-05T21:36:23Z","author_name":"Dave MacLean","url":"/feed/141736","canonical_url":"https://wefunder.com/feed/141736"},{"id":141650,"entity_id":"wefunder:feed_item:141650","type":"FeedItem::Update","visibility":"public","title":"Investment Closing Soon!","preview":"We will be closing this offering later this month. Details will follow in the coming days.","published_at":"2021-02-02T20:16:58Z","author_name":"Dave MacLean","url":"/feed/141650","canonical_url":"https://wefunder.com/feed/141650"},{"id":141600,"entity_id":"wefunder:feed_item:141600","type":"FeedItem::Update","visibility":"public","title":"Quadrant Partners with SUNY Upstate to Build New COVID-19 Lab in Buffalo!","preview":"Exciting news!\u0026nbsp;Quadrant Biosciences and\u0026nbsp;SUNY Upstate Medical University are partnering on the\u0026nbsp;construction of\u0026nbsp;a new COVID-19 testing\u0026nbsp;lab at the University at Buffalo\u0026nbsp;to increase capacity and speed up analysis of our Clarifi\u0026nbsp;COVID-19 saliva test. The new lab,\u0026nbsp;expected to open March 1,\u0026nbsp;increases our testing capacity by 75%, potentially increasing total testing to as many as\u0026nbsp;350,000 tests per week!\u0026nbsp;The new lab will be staffed by Quadrant Bio...","published_at":"2021-02-01T19:36:42Z","author_name":"Dave MacLean","url":"/feed/141600","canonical_url":"https://wefunder.com/feed/141600"},{"id":141502,"entity_id":"wefunder:feed_item:141502","type":"FeedItem::Update","visibility":"public","title":"Quadrant and SUNY Upstate Project of the Year Award Update","preview":"As you may recall,\u0026nbsp;MedTech recently\u0026nbsp;named the\u0026nbsp;Clarifi COVID-19 diagnostic saliva test, co-developed by\u0026nbsp;Upstate Medical and Quadrant Biosciences,\u0026nbsp;as the 2020\u0026nbsp;Project of the Year! The honor was \"awarded to an initiative that has had a singular and demonstrable positive impact on public health.\"\u0026nbsp;In this video clip, SUNY Upstate President Dr. Mantosh Dewan and Quadrant CEO Rich Uhlig provide their thoughts about this recent\u0026nbsp;honor. Click here or on the image...","published_at":"2021-01-28T17:03:59Z","author_name":"Dave MacLean","url":"/feed/141502","canonical_url":"https://wefunder.com/feed/141502"},{"id":140904,"entity_id":"wefunder:feed_item:140904","type":"FeedItem::Update","visibility":"public","title":"An Interview with Rich Uhlig: \"RNA breakthroughs in autism, concussions, and COVID-19\"","preview":"Quadrant Founder and CEO Rich Uhlig was recently\u0026nbsp;interviewed on the DNA Genotek podcast \"Molecules, Microbes and Multiomics.\" The interview covered our collaboration with DNA Genotek, and\u0026nbsp;our work developing\u0026nbsp;RNA based diagnostic tools for autism, concussion and COVID-19. Check out the podcast here!As always, we appreciate the support of each and every one of our investors! If you have not yet invested, please consider joining us on this journey!","published_at":"2021-01-12T17:32:52Z","author_name":"Dave MacLean","url":"/feed/140904","canonical_url":"https://wefunder.com/feed/140904"},{"id":140645,"entity_id":"wefunder:feed_item:140645","type":"FeedItem::Update","visibility":"public","title":"MedTech salutes the Clarifi COVID-19 Saliva Swab as Project of theYear!","preview":"Starting the New Year off with some more great company\u0026nbsp;news!\u0026nbsp;MedTech\u0026nbsp;has\u0026nbsp;named the Upstate and Quadrant Biosciences Clarifi\u0026nbsp;COVID-19 diagnostic saliva test as Project of the Year!\u0026nbsp;\u0026nbsp;The honor is \"awarded to an initiative that has had a singular and demonstrable positive impact on public health.\" MedTech\u0026nbsp;is a\u0026nbsp;state-wide trade association of more than 100 pharmaceutical, biotech and medical technology companies, their suppliers and services providers,...","published_at":"2021-01-01T18:07:27Z","author_name":"Dave MacLean","url":"/feed/140645","canonical_url":"https://wefunder.com/feed/140645"},{"id":140253,"entity_id":"wefunder:feed_item:140253","type":"FeedItem::Update","visibility":"public","title":"SUNY Upstate Medical University to partner with New York Power Authority to test essential utility workers using the Clarifi COVID-19 saliva test","preview":"State University of New York Chancellor Jim Malatras joined with Upstate Medical President Mantosh Dewan, M.D., and New York Power Authority President and CEO Gil C. Quiniones in announcing a mandatory COVID-19 testing program for NYPA’s utility employees who are essential to the operation and maintenance of the statewide power system. The testing program will use the\u0026nbsp;Clarifi COVID-19 Saliva Test Kit developed by SUNY Upstate and Quadrant Biosciences!\u0026nbsp;\u0026nbsp;Image of SUNY Chancellor\u0026...","published_at":"2020-12-30T17:33:27Z","author_name":"Dave MacLean","url":"/feed/140253","canonical_url":"https://wefunder.com/feed/140253"},{"id":140251,"entity_id":"wefunder:feed_item:140251","type":"FeedItem::Update","visibility":"public","title":"Albany Airport Begins Offering the Clarifi COVID-19 Saliva Test to Arriving Passengers","preview":"The Albany International Airport, which two weeks ago began offering our Clarifi COVID-19\u0026nbsp;saliva tests to airport employees, on Wednesday began rolling out voluntary tests to passengers arriving\u0026nbsp;at the airport.\u0026nbsp;“COVID testing of air travelers is the latest component of our Safe Airport approach to the pandemic and exemplifies Albany International Airport’s continued effort to ensure the safety and wellbeing of our passengers and staff.”\u0026nbsp;\u0026nbsp;--\u0026nbsp;Philip Calderone, CEO ...","published_at":"2020-12-28T22:59:16Z","author_name":"Dave MacLean","url":"/feed/140251","canonical_url":"https://wefunder.com/feed/140251"},{"id":139863,"entity_id":"wefunder:feed_item:139863","type":"FeedItem::Update","visibility":"public","title":"Investor Update from CEO Rich Uhlig","preview":"I hope you and your families are continuing to stay safe and healthy. While I know it has only been a few weeks since I last shared a company update, we have had a spate of great news recently that I wanted to share with you.FDA ranks Clarifi COVID-19 test as the most sensitive saliva testFirst, and perhaps most significantly, the recently updated FDA SARS-CoV-2 Reference Panel ranked the Clarifi Covid-19 Test Kit from SUNY Upstate Medical and Quadrant Biosciences as the most sensitive saliva...","published_at":"2020-12-16T21:17:39Z","author_name":"Dave MacLean","url":"/feed/139863","canonical_url":"https://wefunder.com/feed/139863"},{"id":139659,"entity_id":"wefunder:feed_item:139659","type":"FeedItem::Update","visibility":"public","title":"FDA ranks Quadrant Covid-19 saliva test as most sensitive on market!","preview":"\u0026nbsp;More exciting news to share!\u0026nbsp;The recently updated FDA SARS-CoV-2 Reference Panel ranked the Clarifi COVID-19 Test Kit from Upstate Medical and Quadrant Biosciences as the most sensitive saliva test currently on the market! Why is this important?\u0026nbsp;Tests with higher Limits of Detection (LoD) could miss more infected patients resulting in more false negatives. A recent study has suggested that every 10-fold increase in LoD is expected to increase the false negative rate of a test ...","published_at":"2020-12-09T22:07:31Z","author_name":"Dave MacLean","url":"/feed/139659","canonical_url":"https://wefunder.com/feed/139659"},{"id":139490,"entity_id":"wefunder:feed_item:139490","type":"FeedItem::Update","visibility":"public","title":"Quadrant Biosciences Featured at Amazon Web Services Annual Conference","preview":"Quadrant Biosciences was recently\u0026nbsp;recognized in this year's\u0026nbsp;Amazon AWS re:Invent 2020 conference by\u0026nbsp;AWS Channel Chief\u0026nbsp;Doug Yeum in his\u0026nbsp;keynote address!\u0026nbsp;Mr. Yeum spoke about how Quadrant successfully collaborated with AWS partner Innovative Solutions to optimize our diagnostics platform and reduce operating costs by 70 percent. Using the newly optimized diagnostics platform, Quadrant has successfully tested over a half-million people to date. We are honored to be ...","published_at":"2020-12-07T18:48:06Z","author_name":"Dave MacLean","url":"/feed/139490","canonical_url":"https://wefunder.com/feed/139490"},{"id":139480,"entity_id":"wefunder:feed_item:139480","type":"FeedItem::Update","visibility":"public","title":"From Wall Street to Molecular Diagnostics... Learn How It All Started!","preview":"A recent news story in NNY360 provides a great overview of CEO Rich Uhlig's professional career and how Quadrant Biosciences\u0026nbsp;came to be.\u0026nbsp; From growing up in a small,\u0026nbsp;rural town in northern New York State, to a long and\u0026nbsp;distinguished career in finance on\u0026nbsp;Wall Street, to most recently\u0026nbsp;founding and running Quadrant Biosciences- I think you'll find it\u0026nbsp;an interesting story!\u0026nbsp;Check out the Rich Uhlig/Quadrant Biosciences \"origin story\" here.\u0026nbsp;","published_at":"2020-12-02T19:43:38Z","author_name":"Dave MacLean","url":"/feed/139480","canonical_url":"https://wefunder.com/feed/139480"},{"id":139145,"entity_id":"wefunder:feed_item:139145","type":"FeedItem::Update","visibility":"public","title":"Investor Update from CEO Rich Uhlig","preview":"I hope that you and your families are healthy and safe. I wanted to take this opportunity to provide you with an update on our extraordinary progress the past several months, especially under these unique and challenging circumstances. As most of you know, our company looks quite a bit different today than it did just nine months ago. Within months of launching the world’s first saliva test for autism spectrum disorder, Clarifi ASD, the world was besieged by the COVID-19 pandemic and its econ...","published_at":"2020-11-22T18:33:39Z","author_name":"Dave MacLean","url":"/feed/139145","canonical_url":"https://wefunder.com/feed/139145"},{"id":139018,"entity_id":"wefunder:feed_item:139018","type":"FeedItem::Update","visibility":"public","title":"Interview with Dr Steve Hicks About Groundbreaking Saliva Test to Diagnose Concussion","preview":"Watch this interview with Dr. Steve Hicks, associate professor of Pediatrics at Penn State College of Medicine, about the groundbreaking saliva test being developed with Quadrant Biosciences\u0026nbsp;to diagnose concussions and predict how long symptoms will last. Exciting stuff!https://www.fox43.com/article/news/health/spit-test-may-diagnose-concussions-in-athletes/521-86cb29d...","published_at":"2020-11-16T17:14:36Z","author_name":"Dave MacLean","url":"/feed/139018","canonical_url":"https://wefunder.com/feed/139018"},{"id":138527,"entity_id":"wefunder:feed_item:138527","type":"FeedItem::Update","visibility":"public","title":"Quadrant Biosciences Assisting SUNY Testing 140,000 Students for COVID-19 Before Thanksgiving Break!","preview":"Things are going to get even busier\u0026nbsp;at Quadrant Biosciences during the next several weeks!\u0026nbsp;The Chancellor of the\u0026nbsp;State University of New York announced today a policy\u0026nbsp;mandating all students using on-campus facilities in any capacity test negative for COVID-19 within the 10 days prior to leaving campus. \u0026nbsp;As a result,\u0026nbsp;64 SUNY\u0026nbsp;colleges and universities will test about 140,000 students over a 10-day period preceding Thanksgiving break.\u0026nbsp;And Quadrant Bioscien...","published_at":"2020-10-28T17:57:47Z","author_name":"Dave MacLean","url":"/feed/138527","canonical_url":"https://wefunder.com/feed/138527"},{"id":138408,"entity_id":"wefunder:feed_item:138408","type":"FeedItem::Update","visibility":"public","title":"Quadrant Analyzing Wastewater for COVID-19 at Two Colleges in Rochester, NY","preview":"More\u0026nbsp;news about our involvement in\u0026nbsp;wastewater testing in New York!\u0026nbsp;\u0026nbsp;Quadrant is now\u0026nbsp;analyzing wastewater\u0026nbsp;samples from\u0026nbsp;two Rochester, NY colleges \u0026nbsp;- Rochester Institute of Technology and\u0026nbsp;St John Fisher - to\u0026nbsp;identify and track the presence of COVID-19 on their campuses.\u0026nbsp;Wastewater surveillance acts as an early warning system for COVID-19 by detecting the presence of viral RNA shed into the sewer systems. Analysis of wastewater samples can p...","published_at":"2020-10-22T16:25:26Z","author_name":"Dave MacLean","url":"/feed/138408","canonical_url":"https://wefunder.com/feed/138408"},{"id":138363,"entity_id":"wefunder:feed_item:138363","type":"FeedItem::Update","visibility":"public","title":"New Study Suggests Saliva May Hold Key to Concussion Diagnosis","preview":"A simple saliva swab may hold the key to diagnosing and managing mild traumatic brain injury (i.e.\u0026nbsp;concussions),\u0026nbsp;according to a recent\u0026nbsp;study published in the journal\u0026nbsp;Clinical and Translational Medicine.\u0026nbsp;\u0026nbsp;The study,\u0026nbsp;supported by a sponsored research agreement between Quadrant Biosciences and the Penn State College of Medicine, found that\u0026nbsp;a\u0026nbsp;saliva test demonstrated similar diagnostic accuracy to neurocognitive and balance tests commonly used today, a...","published_at":"2020-10-21T21:49:01Z","author_name":"Dave MacLean","url":"/feed/138363","canonical_url":"https://wefunder.com/feed/138363"},{"id":138347,"entity_id":"wefunder:feed_item:138347","type":"FeedItem::Update","visibility":"public","title":"Siena College Sending Wastewater Samples to Quadrant Biosciences for COVID-19 Analysis","preview":"More news today\u0026nbsp;about our COVID-19 testing projects!\u0026nbsp; Siena College\u0026nbsp;is participating in a student initiated wastewater testing program and Quadrant is handling all the\u0026nbsp;lab analysis. Watch the video here!Stay tuned for more updates and, if you haven't\u0026nbsp;already, please consider joining us as an investor!\u0026nbsp;","published_at":"2020-10-20T16:22:26Z","author_name":"Dave MacLean","url":"/feed/138347","canonical_url":"https://wefunder.com/feed/138347"},{"id":138259,"entity_id":"wefunder:feed_item:138259","type":"FeedItem::Update","visibility":"public","title":"Quadrant Involved in Comprehensive Covid Testing at Alfred State College","preview":"As you may know,\u0026nbsp;Quadrant Biosciences is engaged in three, integrated solutions to address\u0026nbsp;COVID-19: 1) individual saliva\u0026nbsp;testing, 2)\u0026nbsp;pooled saliva\u0026nbsp;surveillance and 3)\u0026nbsp;wastewater monitoring. \u0026nbsp;So its extremely gratifying for us when we see\u0026nbsp;all three of these testing protocols successfully\u0026nbsp;implemented by an institution. \u0026nbsp;In this case, Alfred State College has\u0026nbsp;added\u0026nbsp;wastewater testing as an early warning detection system to helps guide ...","published_at":"2020-10-19T19:48:54Z","author_name":"Dave MacLean","url":"/feed/138259","canonical_url":"https://wefunder.com/feed/138259"},{"id":138196,"entity_id":"wefunder:feed_item:138196","type":"FeedItem::Update","visibility":"public","title":"In case you missed it... watch this to catch up on some recent company news!","preview":"In case you missed it... \u0026nbsp;Since we closed our Reg A plus round\u0026nbsp;back in August, a lot of exciting things have\u0026nbsp;happened at Quadrant Biosciences.\u0026nbsp;\u0026nbsp;Watch this short video\u0026nbsp;to learn about some\u0026nbsp;of these highlights!\u0026nbsp;/e72579ce78","published_at":"2020-10-14T16:17:13Z","author_name":"Dave MacLean","url":"/feed/138196","canonical_url":"https://wefunder.com/feed/138196"},{"id":138136,"entity_id":"wefunder:feed_item:138136","type":"FeedItem::Update","visibility":"public","title":"Off to a great start!","preview":"Off to a great start!","published_at":"2020-10-12T18:15:34Z","author_name":"Dave MacLean","url":"/feed/138136","canonical_url":"https://wefunder.com/feed/138136"}],"q_and_a":[{"id":85216,"entity_id":"wefunder:comment:85216","question":"Couple of questions: - Says here that you raised $30M in total or around $24M in 2019. Your cash equivalent is $3.1M. That's an annualized $4.8M net burn rate (after revenues) since 2015 when the company was founded. That's an extremely high burn for not much R\u0026amp;D (since you are licensing the technology from Upstate Medical University and Penn State). Where is the money being spent on? - On your P\u0026amp;L 2018 had $90K in sales, but 2019 had $0. Why the sudden drop? - Also on your P\u0026amp;L salary and wages for 2019 was $1.9M. It states you have 40 employees which averages out to $47K/year in annual base salary. Something doesn't add up. Can you clarify? - I don't see any M.D. / Ph.D. on the executive team outside of Alexandar, but he's a bioinformatician and NOT a wet lab specialist which is needed for the spit test you are developing. Why is this? - $266M pre money seems extremely rich. What's the exit strategy here? I also did not see any total addressable market (bottoms up analysis) available for how much revenue the company can generate. Any details here? - I don't see anything in the deck that mentions insurance reimbursements and receiving approval for it. This is a huge deal, why hasn't it been shown?","author_name":"Richard Lin","votes":11,"created_at":"2020-04-07T17:38:21Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-85216","answers":[{"id":85229,"entity_id":"wefunder:comment:85229","answer":"Hi Richard, Great questions. While we did license the initial (pilot) technology from SUNY Upstate and the Penn State College of Medicine in 2015, we've spent the past 5 years doing clinical research alongside these institutions as well as several others (our NIH Phase II grant related to Autism Spectrum Disorder also includes Cincinnati Children’s Hospital, University of Missouri, and Texas Children’s Hospital). In addition to these institutions, we have several other clinical research sites within and outside the US. We now have more than 1,100 patients aged 18-83 months that are part of our ASD study which includes deeply phenotyped children who are either (i) diagnosed as ASD per DSM5 criteria, (ii) have non-ASD developmental delays, or (iii) are neurotypical. In addition to this work, we have (a) over 300 patients in our multi-center Parkinson’s Disease study, including patients clinically diagnosed as PD, those who have non-PD movement disorders and typically aging adults, (b) over 1,400 samples from patients in our concussion/TBI study and (c) several hundred geriatric patients in our fall-risk/early cognitive decline study (not to mention our work in Anorexia Nervosa). For each of our major areas of interest, we gather deep phenotypic data along with medical histories and demographic data and combine this with full-shotgun sequencing epigenetic data (about 8-10mm transcripts aligned to the human genome (miRNA, piRNA, circRNA, etc.) as well as the microbiome (bacteria, virus, archaea, phage, etc.); in a growing portion of our database, we have full exome sequencing data as well. More detail about our methodologies can be derived from the following published work titled “Validation of a Salivary RNA Test for Childhood Autism Spectrum Disorder” available here: https://www.frontiersin.org/articles/10.3389/fgene.2018.00534/full For our wet-lab work, we are closely partnered with the SUNY Molecular Analysis CORE facility and the faculty at SUNY Upstate Medical University (in fact, we’re down the hall from the CORE facility and typically use about 80% of their sequencing capacity). If you notice in our offering circular, the Research Foundation for the State University of New York is a major shareholder of Quadrant Biosciences. We have a similar research relationship with the Penn State College of Medicine. If you review our 14 peer-reviewed publications (available here: https://www.quadrantbiosciences.com/research/ ), you’ll better understand the number and breadth of MDs and PhDs that are part of our team at Quadrant. In December 2019, we sold over 1 million shares to sophisticated high-net worth individuals at a valuation of $222 million. Since then, we’ve achieved some major milestones, including the initiation of sales of Clarifi ASD (we received CLIA regulatory approval in late November): Clarifi ASD is now offered in more than 130 clinics in 30 states. Equally as significant, we received a Proprietary Laboratory Analyses (PLA) code from the American Medical Association on December 30, 2019 (this code is now active). As you know, our receipt of this PLA code is critical for both medical coding and reimbursement purposes. With over 600,000 US children a year experiencing developmental delays and nearly 65,000 with Autism Spectrum Disorder, our mission to help improve the lives of children and their families is quite significant. Lastly, while some of our payroll is expensed, about half is capitalized – please fee free to contact us directly if you are unfamiliar with GAAP in this regard. I hope I answered your questions – and I hope you choose to join us as an investor! With kind regards, Rich","author_name":"Richard Uhlig","votes":1,"created_at":"2020-04-07T19:03:59Z"}]},{"id":83143,"entity_id":"wefunder:comment:83143","question":"The autism saliva test sounds exciting and surely adds value to the company--but I also know that a big part of the value of a company is the product pipeline. What, if anything, does Quadrant Biosciences have in the pipeline?","author_name":"Deb Pimentel","votes":9,"created_at":"2020-03-19T21:55:50Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-83143","answers":[{"id":83177,"entity_id":"wefunder:comment:83177","answer":"Hi Deb, We think that Clarifi ASD is very exciting too! This is game-changing technology that can improve the lives of millions of children and their families. Our research and development efforts use the same underlying technology - evaluating epigenetic molecules found in the saliva - for the rapid and early diagnosis of several other neurological conditions, including Parkinson's Disease and Concussion Injuries. Some of our peer-reviewed research in these areas include: The oral microbiome of early stage Parkinson’s disease and its relationship with functional measures of motor and non-motor function https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597068/ , and Comparison of serum and saliva miRNAs for identification and characterization of mTBI in adult mixed martial arts fighters https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314626/ . In short, we've got a very exciting product pipeline! Thank you for the excellent question. Sincerely, Rich","author_name":"Richard Uhlig","votes":6,"created_at":"2020-03-19T23:50:12Z"}]},{"id":110076,"entity_id":"wefunder:comment:110076","question":"Hi, As an investor in previous round, What was the valuation of the company in the last round vs current round ? And why do we need more capital considering the capital accumulated from last round was supposed to give you a runway for sometime ? Is this just because of COVID-19 projects ? Whats happening with the original idea of the business that I signed up for","author_name":"Ashish Gupta","votes":3,"created_at":"2020-10-12T17:14:39Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-110076","answers":[{"id":110165,"entity_id":"wefunder:comment:110165","answer":"Thanks for your question Ashish. The company’s valuation is based on the number of outstanding shares of the company and the price per share most recently paid by investors. The price per share in our Regulation A offering was $3 share, and this is the price at which our valuation was calculated; as we have not since offered any shares the company’s valuation remains unchanged. Our current Regulation CF offering of convertible promissory notes with an interest rate of 6% per year and a stated maturity date of August 25, 2025. The notes will convert to common shares of the company at a 20% discount to the share price or equivalent, upon maturity or an earlier (i) \"change of control\" of the company, or a “qualified equity financing” by the company, as more fully described in the actual form of convertible note. The company’s “pre-Covid” business plan remains the same, but as you know the Covid pandemic resulted in our pivoting our efforts towards the development of our suite of Covid test products. Although the company has achieved some significant recent commercial success through the sale of its suite of Covid test products, the company’s management believes its epigenetic diagnostic products are central to the company’s long term prospects and that it is prudent, and in the company’s and shareholders’ best interest, for the company to continue to raise funds, so as to maintain sufficient liquidity to fund its ongoing businesses and operations. Sincerely, Richard Bongo","author_name":"Richard Bongo","votes":1,"created_at":"2020-10-13T16:42:06Z"}]},{"id":150700,"entity_id":"wefunder:comment:150700","question":"Will I see a return on my investment soon?","author_name":"Anton Fernsler","votes":2,"created_at":"2021-05-25T13:25:07Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-150700","answers":[]},{"id":84535,"entity_id":"wefunder:comment:84535","question":"Hello, Is there an intent of going public in the near future? If yes, can you provide an estimate time frame? Thanks","author_name":"Giancarlo Coronado","votes":2,"created_at":"2020-03-31T22:15:23Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-84535","answers":[{"id":84538,"entity_id":"wefunder:comment:84538","answer":"Hi Giancarlo, As you can likely intuit, this offering presages our intended public listing. As you may know, many of the requirements to offer securities in this Regulation A offering conform to the high standards of a public offering (i.e. financial statements audited by a PCAOB certified accounting firm); this offering will help us achieve other listing requirements as well (i.e. to list on NASDAQ, companies must also have at least 450 round lot shareholders or 2,200 total shareholders). Great question - I hope you choose to join us as an investor! Sincerely, Rich","author_name":"Richard Uhlig","votes":0,"created_at":"2020-03-31T22:29:34Z"}]},{"id":310804,"entity_id":"wefunder:comment:310804","question":"I invested in your companyb5 years ago. Now you are shutting down. I want my investment back or I will pursue it legally and file for treble damages","author_name":"Dan Mills","votes":1,"created_at":"2025-07-03T16:29:42Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-310804","answers":[]},{"id":289567,"entity_id":"wefunder:comment:289567","question":"It looks like Quadrant Biosciences is bankrupt or insolvent. I would appreciate any update here from the company and WeFunder.","author_name":"Jesus M. Pizarro Rodriguez","votes":1,"created_at":"2024-08-05T22:32:16Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-289567","answers":[]},{"id":266618,"entity_id":"wefunder:comment:266618","question":"You have provided zero updates or information about the company. If you are bankrupt, please advise WeFunder, as the investors need to write off their investment interest.","author_name":"Elizabeth  Lumbattis-Chalem","votes":1,"created_at":"2023-10-23T22:44:48Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-266618","answers":[{"id":266671,"entity_id":"wefunder:comment:266671","answer":"Morning Elizabeth, I hope all is well. Quadrant is doing well, and we have been emailing individual investor updates quarterly. Please send me your email address, and I will verify that KoreConX, our Registrar, has your correct information. Thanks, Rich Bongo, CFO","author_name":"Richard Uhlig","votes":0,"created_at":"2023-10-24T14:23:35Z"}]},{"id":232498,"entity_id":"wefunder:comment:232498","question":"Echoing a fellow investor's question, is there an update?","author_name":"Anthony Veloso","votes":1,"created_at":"2023-01-27T19:13:41Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-232498","answers":[]},{"id":209145,"entity_id":"wefunder:comment:209145","question":"Hi, I’m just looking for an update of my investment","author_name":"Rachid Assebbane","votes":1,"created_at":"2022-06-22T17:38:23Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-209145","answers":[]},{"id":202094,"entity_id":"wefunder:comment:202094","question":"How do I register?","author_name":"Isaiah Fomunyam","votes":1,"created_at":"2022-04-21T21:02:22Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-202094","answers":[]},{"id":175591,"entity_id":"wefunder:comment:175591","question":"Are you going to start selling Clarifi COVID-19 Test Kits directly to individual customers?","author_name":"Ariel Jay Newman","votes":1,"created_at":"2021-10-24T03:59:09Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-175591","answers":[]},{"id":160711,"entity_id":"wefunder:comment:160711","question":"I invested. When do i receive updates, ? etc","author_name":"Diane Choquette","votes":1,"created_at":"2021-07-31T15:43:32Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-160711","answers":[]},{"id":138371,"entity_id":"wefunder:comment:138371","question":"How do I get information about Quadrant Biosciuences shares I purchased through Wefunder?","author_name":"Sharon Hicks","votes":1,"created_at":"2021-03-29T12:47:34Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-138371","answers":[]},{"id":134587,"entity_id":"wefunder:comment:134587","question":"is it too lat invest in this product?","author_name":"Linda Chu Mei","votes":1,"created_at":"2021-03-12T05:34:43Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-134587","answers":[]},{"id":131080,"entity_id":"wefunder:comment:131080","question":"Do you own the Intellectual Property related to these tests or is it a 100% license situation? I see you did license the initial (pilot) technology from SUNY Upstate and the Penn State College of Medicine in 2015, but have you built upon it to get some of your own patents expanding upon the platform?","author_name":"Douglas G Mancosky","votes":1,"created_at":"2021-02-17T16:11:43Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-131080","answers":[]},{"id":130812,"entity_id":"wefunder:comment:130812","question":"Couple Questions: Is the 6% interest paid out during the term or is it accrued into the value of the note? Second, can you point me to a technical slide deck on how the technology is implemented commercially. For example, is there a capital equipment purchase required to run test or does it use standard equipment? PCR based? How many targets for the ASD product, vs. others? Is there a pipeline for POC implementation with a sample-to-answer cassette/cartridge envisioned? I have experience both in saliva Dx and POC and am quite keen on your company.","author_name":"Nathaniel G Butlin","votes":1,"created_at":"2021-02-15T20:14:29Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-130812","answers":[]},{"id":125901,"entity_id":"wefunder:comment:125901","question":"Why are you pursuing an equity crowdfunding offering at this time after raising significant capital through priced rounds, loans, and a bank line of credit? Candid feedback would be appreciated. Thank you.","author_name":"James S Bednash","votes":1,"created_at":"2021-01-22T03:13:02Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-125901","answers":[{"id":126856,"entity_id":"wefunder:comment:126856","answer":"Hi James! Thanks very much for your question. We are big fans of the democratization crowdfunding provides to investors broadly, and we believe the SEC's less burdensome ongoing reporting and compliance requirements for crowdfunding transactions are helpful in enabling small companies such as ours to efficiently raise funds while continuing to primarily focus on moving our businesses forward. Our crowdfunding offerings have also helped us to achieve a broader investor base (including an increased number of “round lot” investors), which may ultimately be helpful to us in satisfying listing requirements to have our shares listed on a national securities exchange. We also believe that the SEC’s recent actions to permit issuers to raise more money through crowdfundings, and to provide investors with greater access to the crowdfunding markets will further energize these markets. Crowdfunding also provides us with a great opportunity to efficiently share information about our products, aspirations and our evolving business with a broad group of folks who may both use, and benefit from our products (eg: parents who feel that our Clarifi ASD test could be helpful in the early diagnosis of their children as either having ASD or merely being late developing, and in permitting them to pursue early intervention and therapies for their children; or laboratories or institutions (such as schools, businesses, etc.) who might benefit from using our Clarifi ASD saliva test for Covid-19 (which the FDA recently ranked as the most sensitive saliva diagnostic test for Covid-19), and/or who may decide to join us as investors. Although we have, as you’ve noted, to date raised substantially more funds in traditional financings than we have in crowdfundings, we feel our crowdfunding efforts have been very successful and helpful to Quadrant's overall business and prospects and so too our investors’ prospects. I hope these answers are helpful, and I hope you will consider joining us as an investor! Kind regards, James J. Croke — general counsel","author_name":"James Croke","votes":0,"created_at":"2021-01-27T23:35:37Z"}]},{"id":123073,"entity_id":"wefunder:comment:123073","question":"Under the Risks section you include: \"The company may face substantial competition from a number of known and unknown competitors as well as the risk that one or more of them may obtain patents covering technology critical to the company’s businesses.\" Do you not have any patents protecting this method of diagnosing diseases using a saliva-based test?","author_name":"G. K.","votes":1,"created_at":"2021-01-05T19:57:28Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-123073","answers":[{"id":123193,"entity_id":"wefunder:comment:123193","answer":"Thanks for your question Grant! Quadrant does have a number of patent applications pending with respect to the epigenetic products under development for evaluation of ASD, TBI, and Parkinson's. The “Intellectual Property” subsection of our Reg CF offering memorandum describes these filings, and our other intellectual property rights, in some detail and you may find that information to be helpful in providing a more detailed and complete answer to your question. However, as you've noted, the \"Risk Factors\" portion of our offering memorandum (and in particular the \"Risks Related to our Intellectual Property” subsection) correctly cautions that the prosecution of these patent applications is in the early stages and presently it is not known whether patents will be issued based on the applications. Furthermore, even if one or more patents are issued based on the pending applications, it is not known how broad the claims will be. The primary type of claims that are being prosecuted in the pending patent applications are method claims, which range from broad claims with few limitations to narrow claims with more limitations. It is very difficult to obtain broad method claims in this field of technology. To the extent that a patent is issued with fairly narrow claims, it is feasible that competitors can \"design around\" the claims and engage in competitive activity that does not copy Quadrant's methods but is similar to them. The competitive advantage obtained from a patent depends on the extent to which a competitor's design around results in an inferior product or a method's inferior performance. Therefore, the degree of competitive advantage that Quadrant will obtain from prosecution of its pending patent applications is presently not known and the competitive risks described in the offering materials should be considered. I hope these answers are helpful. Thanks for your interest in Quadrant Biosciences! I hope you’ll consider joining us as an investor! Kind regards, James J. Croke -- general counsel","author_name":"James Croke","votes":0,"created_at":"2021-01-06T10:42:30Z"}]},{"id":119754,"entity_id":"wefunder:comment:119754","question":"Hi, is there a date to when the company will start trading publicly on the stock market?","author_name":"Alexandre Siriwardhana","votes":1,"created_at":"2020-12-16T22:23:32Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-119754","answers":[{"id":119880,"entity_id":"wefunder:comment:119880","answer":"Hi Alexandre! Thanks for your question. There is not yet a fixed date by which Quadrant's common shares will start trading publicly on a stock market, but we are very focused on moving forward in a manner that will provide our shareholders with secondary market liquidity (eg, a listing of our shares on a national stock exchange) as early as practicable. We currently believe our investors will be best served in the long run if we continue, for now, to focus most of our time, energy and resources on continuing to develop and commercialize our products. We are working hard to develop molecular diagnostic tests that will improve and protect the lives of many, while generating value for all our shareholders (including our convertible note holders, whose shares will convert to common shares). I hope this answer is helpful - thanks for your interest in Quadrant Biosciences! Kind regards, Jim","author_name":"James Croke","votes":0,"created_at":"2020-12-17T14:37:28Z"}]},{"id":119366,"entity_id":"wefunder:comment:119366","question":"This may seem rather basic but; is the share price available for investment now, equivalent to earlier investors and the large buy in of over 1,000,000 shares . I.E. am I paying the same share per price today as others paid months or years ago? Second. Do the corporate documents allow for share dilution via the issuance of additional shares in the future or the use of shares to attract executive talent? Last. Where is the full Deck available?","author_name":"Richard Holmes","votes":1,"created_at":"2020-12-14T21:13:26Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-119366","answers":[{"id":119726,"entity_id":"wefunder:comment:119726","answer":"Hi Richard! Thanks very much for your questions. We are currently offering convertible notes, which will convert to common shares at a 20% discount to the common share price, or its equivalent, at the time of conversion. As we are not currently offering common shares there is no price at which our common shares may be obtained through our current Reg CF offering. Our most recent common share offering prices were $3.00/share (in a Regulation A offering through Wefunder which closed in August of this year) and $2.50/share (in a private placement which closed in February of this year). If you have an interest in acquiring a large block of our common shares (eg, 1,000,000 shares) please let us know, and we will be happy to discuss your requested investment. Our corporate documents permit us to issue common shares for any authorized purpose, subject to the issuance being authorized by our board of directors, consistent with our articles of incorporation. Share issuances would generally be expected to result in some dilution, but to the extent we believe that additional funding is needed or could be helpful to funding the continued development and commercialization of our existing and new products we may borrow additional funds or issue additional shares or notes. A complete copy of our Reg CF investment deck appears on our Wefunder investor page, under the heading “Downloads”. I hope these answers are helpful. Thanks for your interest in Quadrant Biosciences Inc.! Kind regards, Jim","author_name":"James Croke","votes":0,"created_at":"2020-12-16T20:05:31Z"}]},{"id":118272,"entity_id":"wefunder:comment:118272","question":"Hello. Do you folks happen to have a date or month for when your raise is going to end? Thank you.","author_name":"Brian Thomson","votes":1,"created_at":"2020-12-09T19:52:21Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-118272","answers":[{"id":118449,"entity_id":"wefunder:comment:118449","answer":"Thanks very much for your question Brian. We expect the offering to close on or before February 15, 2021. Kind regards, Jim Croke -- general counsel","author_name":"James Croke","votes":0,"created_at":"2020-12-10T11:08:10Z"}]},{"id":114330,"entity_id":"wefunder:comment:114330","question":"With the work you’ve done so far, why not pursue an IPO vs. Crowdfunding?","author_name":"Joseph Marsala","votes":1,"created_at":"2020-11-13T18:57:53Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-114330","answers":[{"id":115235,"entity_id":"wefunder:comment:115235","answer":"Thanks for your question Joseph! I hope the following answer is helpful! In addition to our being big fans of the democratization crowdfunding provides to investors broadly, we believe the SEC's less burdensome ongoing reporting and compliance requirements for crowdfunding transactions are better tailored to small companies such as ours. Although we are very focused on providing our investors with access to secondary market liquidity as soon as practicable, we believe our investors will be better served in the long run if we continue, for now, to focus most of our time, energy and resources on continuing to develop and commercialize our products (vs shifting some substantial portion of our resources towards the administrative obligations we would have as a publicly owned company). With kind regards, Jim Croke -- General Counsel","author_name":"James Croke","votes":1,"created_at":"2020-11-19T17:52:56Z"}]},{"id":111867,"entity_id":"wefunder:comment:111867","question":"how can your covid-19 test be accurate whenever there's no actual data or evidence that shows the virus is real they're just saying it","author_name":"Jonathan Smith","votes":1,"created_at":"2020-10-23T05:06:57Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-111867","answers":[]},{"id":111346,"entity_id":"wefunder:comment:111346","question":"Never mind, I just saw it in an answer to a previous question.","author_name":"Daniel Johnsen","votes":1,"created_at":"2020-10-20T15:11:22Z","canonical_url":"https://wefunder.com/quadrant.biosciences#question-111346","answers":[]}],"faq":[{"question":"Is this fund raising under Regulation A or Title III?","answer":"Hello Ram, Quadrant Biosciences is offering this as a Reg A. Thanks, The Quadrant Team"},{"question":"Hi, Your max raise goal is $15M and you stated \"Quadrant Biosciences Inc is not conducting a Regulation Crowdfunding offering.\" So this is a Reg D offering? Please clarify. Thanks.","answer":"Hello Helen, The Quadrant Team, along with the fine people at Wefunder, has spent countless hours reviewing these pages to make sure nothing has slipped through. That being said, the above stated quote, \"Quadrant Biosciences Inc is not conducting a Regulation Crowdfunding offering\" has been removed from the webpage. We are conducting a Reg A offering. Thank you for pointing this out to us and please accept our apologies. We hope to see you as an investor, The Quadrant Team"},{"question":"What valuation was given to the company in the latest funding round in Dec19?","answer":"Hello William, The valuation of the company following our last Regulation D common stock offering (December 2019) was approximately $222 Million. Please note that the shares purchased in the Regulation D offering in December are subject to 1 year holding period which is a significant liquidity restriction whereas the shares purchased through this Regulation A offering are freely transferable. We hope this explanation is helpful and that you choose to join us as an investor! Thanks, The Quadra..."},{"question":"What's the science behind testing for autism and other disease states that are primarily diagnosed through behavioral patterns?","answer":"Thank you for asking! This is game-changing technology which has been developed over the past 5 years by SUNY Upstate Medical University, the Penn State College of Medicine and Quadrant Biosciences. A quick video about our science is available here: https://vimeo.com/367101683 . Further, we’ve made a commitment to transparency in our work – our 7 peer-reviewed publications related to Autism Spectrum Disorder are available here: https://www.clarifiasd.com/our-science/ (but if you only have tim..."},{"question":"Hello ,is there any plan for future exit ( acquisition or going Public)?","answer":"This is a very savvy question – thank you. As you can likely intuit, this offering presages our intended public listing. As you may know, many of the requirements to offer securities in this Regulation A offering conform to the high standards of a public offering (i.e. financial statements audited by a PCAOB certified accounting firm); this offering will help us achieve other listing requirements as well (i.e. to list on NASDAQ, companies must also have at least 450 round lot shareholders or ..."}]}}}